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Previous imaging and postmortem studies have reported a lower brain volume and a smaller size and density of neurons in the dorsolateral prefrontal cortex (dlPFC) of subjects with major depressive disorder (MDD) 1, 2 . These findings suggest that synapse number and function are decreased in the dlPFC of patients with MDD. However, there has been no direct evidence reported for synapse loss in MDD, and the gene expression alterations underlying these effects have not been identified. Here we use microarray gene profiling and electron microscopic stereology to reveal lower expression of synaptic-function-related genes (CALM2, SYN1, RAB3A, RAB4B and TUBB4) in the dlPFC of subjects with MDD and a corresponding lower number of synapses. We also identify a transcriptional repressor, GATA1, expression of which is higher in MDD and that, when expressed in PFC neurons, is sufficient to decrease the expression of synapse-related genes, cause loss of dendritic spines and dendrites, and produce depressive behavior in rat models of depression.
MDD affects approximately 17 percent of the US population and is predicted to be the number two cause of illness worldwide by the year 2020 (ref. 3) . The symptoms of MDD include cognitive impairment and memory loss, implicating synaptic dysfunction in the pathophysiology of the disorder [4] [5] [6] . This possibility is supported by studies using animal models of depression that have shown a reduction in the number of dendritic spines and in the function of neurons in the PFC 7, 8 . Postmortem studies also report morphometric changes in the PFC of subjects with MDD, including a smaller size of the neuronal bodies 1, 9 . This is also consistent with brain imaging studies reporting a smaller volume of PFC subregions in patients with MDD 2, 10 . Together, these studies suggest a loss of spine number and dendritic arbor in MDD, although there is no direct evidence showing this type of neuronal atrophy in the brains of subjects with MDD.
To gain insight into the mechanisms that underlie the neuronal atrophy and reduced volume of the PFC, we analyzed the data from a prior microarray gene expression study that we conducted of the dlPFCs (Brodmann area 9) of subjects with MDD and matched controls 11 .
We classified the microarray data with a 5% false discovery rate 11 and found that about 30% of the downregulated genes in the MDD group could be related to some aspect of synaptic function. A more extended range (using a 20% false discovery rate cutoff) identified an additional subset of downregulated genes related to synaptic function in the dlPFC of the subjects with MDD ( Supplementary Table 1 ). These synaptic functions include the regulation of synaptic vesicle transport and release (calmodulin 2, synapsin I, synapsin III, Rab3A, amphiphysin and synaptogyrin 3) [12] [13] [14] [15] [16] , the regulation of synaptic strength (neurogranin) 17 , dendritic spine formation (Rab4B) 18 and axonal outgrowth and regeneration (tubulins) 19 . It is notable that other genome-wide expression studies of MDD have reported gene alterations in similar functional categories (such as cytoarchitecture, vesicular transport and synaptic transmission) of some of the same synapse-related genes 20-23 that we identified here (for example, genes encoding subtypes of amphiphysin, synaptogyrin, synapsin and the Ras superfamily) [22] [23] [24] .
A PCR analysis showed significantly lower (P < 0.05) expression for five of the ten genes we identified and trends for lower expression for all but one (amphiphysin) of the remaining genes in the dlPFC of the subjects with MDD as compared to age-matched, nondepressed healthy controls ( Supplementary Table 1 ). An in situ hybridization analysis of the five confirmed genes (CALM2, SYN1, RAB3A, RAB4B and TUBB4) showed lower expression in the gray matter of the dlPFC of the subjects with MDD, with a laminar distribution in the middle (synapsin I) or the middle and deep layers (calmodulin 2, Rab3A, Rab4B and β-tubulin 4) of the dlPFC ( Fig. 1a-e) . A quantitative analysis confirmed that the expression of these five genes was significantly lower in subjects with MDD compared to individuals without MDD (controls) ( Fig. 1a-e ). Studies in rats showed that chronic unpredictable stress (CUS), which is considered one of the most valid rodent models of depression, decreases the expression of CALM2, SYN1, RAB3A and RAB4B, but not that of TUBB4, in the PFC (Supplementary Fig. 1 ), suggesting that the decreased expression of these synapse-related genes in MDD results from chronic stress exposure and that these alterations could contribute to depressive behaviors.
The lower expression of synapse-related genes found here and a previous report of smaller neuronal cell bodies in the dlPFC of l e t t e r s subjects with MDD 1 suggests a reduction in synaptic density in subjects with MDD, although there is no direct evidence to support this possibility. An examination of dendritic morphology using microtubule-associated protein 2 (MAP2) immunohistochemistry revealed less staining of dendritic processes in dlPFC layers III-V of subjects with MDD relative to controls, which we confirmed using MAP2 immunoblotting of micropunches from the dlPFCs ( Fig. 1f,g) . Using electron microscopic stereological analysis, we found a markedly lower number of spine synapses in subjects with MDD compared to controls ( Fig. 1h) . A cofactor analysis revealed no significant effects of medication status, age of first episode (occurring at <40 years of age compared to ≥40 years of age) or suicide on synapse number (Supplementary Figs. 2-4 ).
An examination of the transcription-factor-binding motifs in the promoter regions of the synapse-related genes with decreased expression in MDD identified 3,266 upstream regulatory elements for 218 transcription factors (TRANSFAC scoring matrix; Supplementary  Table 2 ). Twelve transcription-factor-binding sites are localized to the upstream regulatory domain of the five synapse-related genes that are altered in MDD and CUS ( Fig. 2a) . The rat homologs of these synapse-related genes include 8 of the 12 transcription factor regulatory elements ( Fig. 2a and Supplementary Table 3 ). An analysis of the microarray data revealed that the mRNA expression of one of these transcription factors, GATA1, is significantly increased in patients with MDD ( Fig. 2b) . The expression of other transcriptions factors was either not significantly different between individuals with MDD and controls (GKLF and KID3, 1.0-fold and 1.1-fold higher in MDD, respectively) or were not included in the microarray gene set. The expression of the related GATA2, GATA3 and GATA4 subtypes were not significantly altered in individuals with MDD compared to controls (0.96-fold, 1.09-fold and 0.99-fold, respectively). A cofactor analysis revealed no effect of medication status on GATA1 expression and no significant differences in GATA1 expression between the group of all subjects with MDD and subgroups of subjects with MDD categorized by age of first episode, number of episodes and suicide, although the number of subjects per subgroup was small ( Supplementary Figs. 2-5 ). The expression of Gata1 in the PFC was increased in the CUS rat model of depression, which was reversed by chronic administration of the antidepressant fluoxetine ( Fig. 2c) . The ability of antidepressant treatment to normalize GATA1 expression in rats but not in patients with MDD could be the result of the small number of medicated and unmedicated patients, as well as treatment resistance and heterogeneity of the human subjects. We confirmed the binding activity of Gata1 to the promoter of all of the synapse-related genes using chromatin immunoprecipitation (ChIP) with an antibody to Gata1 and then performing PCR for the Gata1-binding region of each gene ( Fig. 2d) .
We examined whether elevated protein expression of GATA1 underlies the decreased expression of the synapse-related genes and the atrophy of dendritic processes in primary neuronal cultures. Our initial studies focused on RAB4B because this small GTPase (of the Rab family) is required for the endosomal recycling that is crucial for the maintenance of spine size 18 and because RAB4B showed the greatest difference in expression between MDD and controls (Supplementary Table 1 ). Infection of cultured rat cortical neurons with a recombinant adeno-associated virus encoding enhanced GFP (eGFP)-tagged GATA1 (rAAV-GATA1-eGFP) compared to control virus (vector only) ( Fig. 3a,b ) resulted in significantly lower expression of Rab4b (Fig. 3c) . The expression of a cofactor target gene, FOG1, that is positively regulated by GATA1 (refs. 25, 26) , was significantly increased by viral expression of GATA1 (P = 0.011). To analyze dendrite morphology, we fixed and labeled neurons with GFP-specific ( Fig. 3d,e ) and MAP2-specific antibodies (Fig. 3f ). Viral expression of GATA1 decreased the complexity of the dendritic arbor ( Fig. 3d) , the number of spines ( Fig. 3e ) and the intensity of the MAP2 staining ( Fig. 3f) , which we confirmed by western blot analysis ( Fig. 3g) . A Sholl analysis showed that viral expression of GATA1 significantly decreased the number of dendrite intersections, indicating decreased complexity ( Fig. 3h) .
We then examined the effects of GATA1 expression on behavior in rat models of depression. We infused the same eGFP-tagged control or rAAV-GATA1-eGFP viral vectors into the PFC of rats ( Fig. 4a) and 5-6 weeks later confirmed the viral expression and location in the medial PFC by assessing GFP expression ( Fig. 4b) . Infusion of rAAV-GATA1 produced depressive-like behaviors in two established rat models. In a forced swim test, infusion of rAAV-GATA1-eGFP increased the time the rats spent immobile, which is a measure of behavioral despair (Fig. 4c) . In the learned helplessness model, exposing animals to inescapable stress causes escape deficits. In the rats we studied here, a single infusion of rAAV-GATA1-eGFP increased the number of escape failures during the initial block of active avoidance testing (trials 1-5), which is similar to the effects of exposure to inescapable stress ( Fig. 4d) . During the second block of active avoidance testing (trials 6-10), there was no significant effect of infusion with rAAV-GATA1-eGFP ( Fig. 4d) , indicating that GATA1 initially delays responses but does not produce a sustained effect in this model. Infusion of rAAV-GATA1-eGFP did npg not influence locomotor activity in the rodents (data not shown), indicating that there was no generalized effect of GATA1 on ambulation. Further studies showed that the effects of rAAV-GATA1-eGFP in the forced swim test were not reversed by treatment with the antidepressant imipramine, which we expected, as drug treatment does not influence the viral expression of GATA1 (Supplementary Fig. 6 ). We next examined the influence of GATA1 on depressive behavior caused by chronic stress using a viral knockdown strategy with an shRNA targeted to GATA1 (rAAV-GATA1 shRNA ) ( Fig. 4e) . We confirmed the ability of rAAV-GATA1 shRNA to decrease Gata1 mRNA levels in cultured cells and rat PFCs (Supplementary Fig. 7) . We infused either rAAV-GATA1 shRNA or a scrambled control shRNA (rAAV-Scr shRNA ) into the PFC (Fig. 4f ) of rats that we then subjected to the CUS paradigm, which has been shown to increase Gata1 mRNA levels (Fig. 2c) . This paradigm results in anhedonia, a core symptom of depression that can be measured by preference for a sweetened solution 27 . In rats infused with control virus (rAAV-Scr shRNA ), CUS exposure led to significantly lower sucrose preference compared to rats not exposed to CUS (Fig. 4g) . This effect of CUS on sucrose preference was blocked by infusion of rats with the vector that decreases Gata1 expression (rAAV-GATA1 shRNA ). rAAV-GATA1 shRNA had no effect in the nonstressed rats not exposed to CUS, indicating that basal levels of GATA1 are low and are not sufficient to suppress the basal rates of sucrose preference.
Using three complementary approaches, we identified and confirmed a subset of synapse-related genes that are repressed in the dlPFC of subjects with MDD. At the presynaptic level, synapsin I, Rab3A and calmodulin 2 regulate the size, number and targeting of synaptic vesicles, and β-tubulins are involved in axonal outgrowth and regeneration 19, [28] [29] [30] [31] . Postsynaptically, Rab4B regulates the endosomal recycling that is required for spine maintenance and neurotransmitter receptor recycling 18, 32 . Consistent with the role of these gene products in synaptic function and structure, our results also show a reduction in the number of synapses in the dlPFC of subjects with MDD. Together, these findings reveal molecular and cellular alterations that could underlie the smaller size of neuronal cell bodies and lower volume of the PFC in patients with MDD 1,10 . Decreased expression of these genes in response to chronic stress exposure also suggests an etiological relationship to MDD, which is often associated with severe life stress and trauma 33, 34 .
We also identified GATA1 as a transcriptional repressor that is increased in MDD and has binding elements in the promoter regions of the synapse-related genes. GATA1 is a member of a zinc finger family of transcription factors that is evolutionarily conserved and has key roles in embryonic development 35 . Although originally characterized in hematopoietic and cardiac tissues, GATA transcription factors are also expressed in endocrine and brain tissue, and have been reported to regulate neuronal differentiation during development [35] [36] [37] [38] . Our viral overexpression and knockdown studies show that expression of Gata1 in the PFC is necessary and sufficient for the development of depressive behaviors in multiple animal paradigms. Further evidence for a role of GATA1 in depression was provided by a recent report of a polymorphism in the GATA1-binding site of the promoter for interleukin-6, an inflammatory cytokine that is increased in depression 39 .
Together, our results describe molecular and cellular mechanisms that are sufficient to cause a reduction in the number of synapses and in dendritic complexity and could contribute to the neuronal atrophy and decreased cortical volume reported in patients with MDD. They suggest that approaches that block or reverse neuronal atrophy in the PFC could be effective antidepressant treatments. This possibility is supported by recent studies showing that the rapid antidepressant actions of NMDA receptor blockade are associated with increased spine synapse number and function and increased synaptogenesis in the PFC 40 .
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Methods and any associated references are available in the online version of the paper. 
Note: Supplementary information is available in the online version of the paper.

ACKnowLeDGMenTS
npg oNLINe MeTHoDs
Human subjects and microarray analysis. The details of postmortem tissue collection, subjects and microarray analysis are exactly as described in our previous study 11 .
Quantitative real-time PCR. An aliquot of the total RNA that was previously extracted from prefrontal cortex punches was used for secondary validation using real-time PCR (the primers used are listed in Supplementary Table 4 ).
Five hundred nanograms of total RNA was used for complementary (cDNA) synthesis using oligo dT primers and SuperScript II reverse transcriptase (Invitrogen) and was subsequently diluted with nuclease-free water to a concentration of 10 ng µl −1 cDNA. Gene-specific, high-melt-temperature primers for the genes of interest were designed using Primer 3 software (http://frodo.wi.mit.edu/; Whitehead Institute for Biomedical Research), and expressed sequence information was obtained from GenBank (NCBI). PCR reactions were conducted on an ABI 7900 Sequence Detection System (Applied Biosystems) using a Hot Start SYBR Green-based method (Quantitect, QIAGEN) followed by a melt curve analysis to verify the specificity of the product. The CT value (cycle number at threshold) was used for the calculations of the relative number of mRNA molecules. The CT value of each target gene was normalized by subtracting the CT value from the CT values of multiple housekeeping genes. This value is the ∆CT. The difference in ∆CT between control (non-MDD) and MDD is the ∆∆CT, and the relative quantitative change was shown as 2 −∆∆CT . All of the genes of interest were normalized to the housekeeping gene PPIA (cyclophilin A).
Electronic microscopic stereology. The number of spine synapses in the dlPFC of postmortem brains was counted as previously described 41, 42 . Briefly, postmortem samples were immersed overnight in a mixture of 2% glutaraldehyde and 4% paraformaldehyde dissolved in phosphate buffer. Vibratome sections 100-µm thick were cut throughout the tissue blocks and embedded in Durcupan (Electron Microscopy Sciences, Fort Washington, PA). Using the embedded sections, at least ten sampling areas were randomly selected from each brain, and ultrathin sections (~70 nm) from each sampling area were prepared with a Reichert Ultracut E microtome. Digitized electron micrographs of each sampling area were taken using a Tecnai 12 transmission electron microscope (FEI company, Hillsboro, OR). Synapses were counted using the dissector technique. Synapse numbers for each brain were obtained by averaging the data from at least ten dissectors.
In situ hybridization. Sections of human brain were cut at 14-µm-thick sections from blocked dlPFC. Rat brains were also sectioned at 14 µm after the rats were euthanized; their brains were then immediately frozen and then were stored at −80 °C. Brains were mounted onto Probe-On Plus glass slides (Fisher Scientific). To prepare the complementary RNA (cRNA) probe for in situ hybridization histochemistry, the fragments of cDNA were amplified by PCR using a T7 promoter-attached primer, and PCR products were used to generate 35 S-radiolabeled riboprobes using T7 RNA polymerase in vitro transcription (Ambion, T7-MEGAshortscript). After fixation and acetylation, human or rat sections were hybridized with 35 S-CTP-incorporated RNA probes at 60 °C for 16 h in the hybridization solution. Sections were then washed at 60 °C, dehydrated with graded alcohols, air dried and exposed to film. Stress and antidepressant model. Rats (all male) were subjected to CUS for 35 d, as previously described 40 ; fluoxetine was administered from day 15 to day 35 (twice a day, 15 mg per kg per treatment, intraperitoneally). Control rats were handled every other day for the first 15 d and then daily for vehicle (saline) administration, and their brains were harvested for in situ hybridization analysis 4 h after the last vehicle or drug treatment. For the stress study with rAAV-GATA1 shRNA , rats were subjected to 3 weeks of CUS stress after the viral infusion. All procedures were done in accordance with the US National Institutes of Health guidelines for the care and use of laboratory animals and the Yale University Institutional Animal Care and Use Committee.
Transcription factor binding motif search. The TRANSFAC scoring matrix (http://www.biobase-international.com) was used for the binding motif search in the promoter regions (1 kb of the 5′ flanking sequence and 200 bp downstream from the transcription start site) of our candidate genes. The over-represented transcription-factor-binding sites were determined in the set of promoters with the parameter of exact matches of core sequences (core score = 1) at 0.95 a matrix similarity cutoff (matrix score ≥0.95) in the vertebrate matrix.
ChIP. Cultured primary cortical neurons (at 7 days in vitro (DIV 7)) were incubated in 1% formaldehyde for 10 min at room temperature for the crosslinking of DNA and DNA-binding proteins. Crosslinked neurons were lysed in SDS lysis buffer (1% SDS, 10 mM EDTA and 50 mM Tris-HCl, pH 8.1) including protease inhibitors and phosphatase inhibitors. Chromatin was sheared by sonication and separated by centrifugation for 10 min at 13,000 rpm. The supernatant was collected and immunoprecipitated with dynabead (Dynal, 112-01D) conjugated with 1 µg of GATA1-specific antibodies (Santa Cruz, sc-265, 2 µg ml −1 ) or normal horse serum overnight at 4 °C. After reverse crosslinking, DNA was eluted using a QIAGEN MinElute Purification Kit and quantified by real-time PCR.
Primary cortical neuron culture. Embryonic brains were prepared from fetal Sprague-Dawley rats after 18 d of gestation and mechanically triturated, as described previously 43 . Dissociated cells were plated on 12-well plates (0.5 × 10 5 cells per well) in plating medium consisting of Neurobasal media supplemented with 10% FBS, 2 mM l-glutamine, 1 mM sodium pyruvate, 1 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 2% Pen-Strep and 2% B27 supplement. Proliferation of non-neuronal cells was halted by replacing with plating medium lacking fetal serum the next day (DIV 1). Cultures were then fed once a week with plating medium lacking fetal serum and maintained at 37 °C in a humidified 5% CO 2 atmosphere.
Generation of rAAV vectors. To generate rAAV-GATA1-eGFP, mouse GATA1 cDNA (1,801 bp) was subcloned in the mammalian expression vector (pXM-GATA1) and inserted into the pAAV-EGFP-pA (5,403 bp) vector by enzyme restriction and ligation. shRNA was designed to specifically target GATA1 mRNA. A 24-bp oligonucleotide sequence within the coding region of the GATA1 gene was identified. Hairpins were designed such that the antisense strand came before the sense strand during transcription. Two sets of oligonucleotides were synthesized (Integrated DNA Technologies, Coralville, Iowa) for cloning: GATA1 shRNA top: 5′-TTTGAAGATGCTGTATCCAAACTCTC ACTTCCTGTCATGAGAGTTTGGATACAGCATCTTATTTTT-3′; bottom: 5′-CTAGAAAAATAAGATGCTGTATCCAAACTCTCATGACAGGAAGTG AGAGTTTGGATACAGCATCTTC-3′. The oligonucleotides had Sap1 and Xba1 overhangs to allow for ligation into mU6pro region of the modified pAAV-MCS vector, pAAV-shRNA. The pAAV-shRNA plasmid was designed to coexpress shRNA and eGFP under the control of an independent RNA polymerase II promoter for enhanced green fluorescent protein and U6 promoter for shRNA. All final clones were verified for sequencing. For virus preparation, HEK 293 cells were cotransfected with pAAV-GATA1-eGFP or pAAV-eGFP, pAAV-Scr shRNA or pAAV-GATA1 shRNA , pAAV-RC and pHelper using the calcium phosphate precipitation method. After 72 h, vectors were purified from cell lysates by iodixanol gradient centrifugation followed by column concentration. Behavioral experiments using rAAV-GATA1 shRNA were performed after ensuring efficient knockdown of GATA1 mRNA in HEK 293 cells. For in vitro validation, plasmids expressing scrambled shRNA (pScr shRNA ) and GATA1 shRNA (pGATA1 shRNA ) were transfected into HEK 293 cells using lipofectamine (Invitrogen) following the manufacturer's instructions. Twentyfour hours after the transfection, RNA was purified using a RNaqueous kit (Ambion), and cDNA was synthesized for qPCR. For in vivo validation, rats were perfused and the medial PFC was microdissected after behavioral testing. Total RNA was extracted from the PFCs using an RNAeasy formalin-fixed paraffin-embedded (FFPE) kit (QIAGEN), and quantitative real-time PCR was performed as described above.
Western blot. Cultured neurons were lysed in radioimmunoprecipitation assay (RIPA) buffer. Protein concentrations were measured using a BCA Protein Assay Kit. Proteins were separated by SDS-PAGE and transferred npg
